Jocasta Neuroscience Lands $35 Million Series A to Advance Longevity Protein Program for Managing Cognitive Impairment
Funding to support development of proprietary * a -Klotho *protein therapeutic targeting cognitive decline in neurodegenerative diseases SCOTTSDALE, Ariz., Aug. 12, 2025 /PRNewswire/ — Jocasta Neuroscience, Inc., a preclinical stage, longevity-focused company, with its lead asset, a proprietary…